Sensei Biotherapeutics (NASDAQ:FTH) Upgraded to “Strong-Buy” at Guggenheim

Sensei Biotherapeutics (NASDAQ:FTH) was upgraded by investment analysts at Guggenheim to a “strong-buy” rating in a report released on Tuesday, Zacks reports.

Other equities research analysts also recently issued research reports about the company. Needham & Company LLC started coverage on Sensei Biotherapeutics in a report on Friday, August 21st. They set a “buy” rating and a $56.00 price objective on the stock. Citizens Jmp started coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $51.00 target price for the company. Loop Capital set a $50.00 target price on Sensei Biotherapeutics in a research report on Thursday, May 28th. TD Cowen began coverage on Sensei Biotherapeutics in a research note on Wednesday, September 9th. They set a “buy” rating on the stock. Finally, Oppenheimer initiated coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $56.25.

Sensei Biotherapeutics Stock Down 3.2%

Shares of Sensei Biotherapeutics stock opened at $34.24 on Tuesday. The firm’s 50 day moving average is $31.94. The company has a market cap of $884.76 million, a price-to-earnings ratio of -0.24 and a beta of -0.28. Sensei Biotherapeutics has a 1 year low of $7.45 and a 1 year high of $42.14.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($5.04) by $2.20. As a group, equities research analysts predict that Sensei Biotherapeutics will post -13.69 EPS for the current year.

Insider Buying and Selling at Sensei Biotherapeutics

In related news, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $19.76 per share, with a total value of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Brian C. Stephenson purchased 9,391 shares of Sensei Biotherapeutics stock in a transaction on Wednesday, June 24th. The stock was bought at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the transaction, the chief financial officer directly owned 26,804 shares in the company, valued at approximately $700,388.52. The trade was a 53.93% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have purchased 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC acquired a new position in Sensei Biotherapeutics in the second quarter valued at $307,000. Renaissance Technologies LLC lifted its stake in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the period. Bank of America Corp DE lifted its stake in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Alyeska Investment Group L.P. bought a new stake in shares of Sensei Biotherapeutics during the 2nd quarter valued at about $3,610,000. Finally, Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics during the 1st quarter valued at about $4,188,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.